RxDoctor Payments Data

Eric Golderman

Family · Schenectady, NYNPI 1639784523

Payments from drug & device makers

$3,453in general payments, 2019–2025

Across 188 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$875
  • AstraZeneca$560
  • Novo Nordisk$342
  • GSK$304
  • Lilly USA, LLC$178
  • Biohaven Pharmaceuticals, Inc.$162
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,453 in reported general payments places this provider in the 90th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$36,914
Medicare patients
271
Services billed
848

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol16$9,837
Albuterol Sulfate HfaAlbuterol Sulfate50$1,622
Ezetimibe12$916
Atorvastatin Calcium56$794
Rosuvastatin Calcium39$572
Omeprazole41$505
Azithromycin73$476
Valsartan13$434
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav41$425
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst41$407
Fluticasone Propionate28$403
Lisinopril66$398
Pravastatin Sodium20$383
Amoxicillin43$351
Metoprolol Succinate26$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$560$9,83716 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$29436 claims
PfizerPaxlovid$117$021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,883 family providers in New York.

Other family in Schenectady

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →